Journal
PLOS ONE
Volume 11, Issue 12, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0167058
Keywords
-
Categories
Funding
- Canadian Institute of Health Research (CIHR) [MOP-111112]
- Health Respiratory Training Program of Quebec
Ask authors/readers for more resources
Inflammation is a major burden in respiratory diseases, resulting in airway hyperresponsiveness. Our hypothesis is that resolution of inflammation may represent a long-term solution in preventing human bronchial dysfunctions. The aim of the present study was to assess the anti-inflammatory effects of RvD(2), a member of the D-series resolving family, with concomitant effects on ASM mechanical reactivity. The role and mode of action of RvD(2) were assessed in an in vitro model of human bronchi under pro-inflammatory conditions, induced either by 1 mu M LTD4 or 10 ng/ml TNF-alpha pre-treatment for 48h. TNF-alpha and LTD4 both induced hyperreactivity in response to pharmacological stimuli. Enhanced 5-Lipoxygenase (5-LOX) and cysteinyl leukotriene receptor 1 (CysLTR1) detection was documented in LTD4 or TNF-alpha pre-treated human bronchi when compared to control (untreated) human bronchi. In contrast, RvD(2) treatments reversed 5-LOX/beta-actin and CysLTR1/beta-actin ratios and decreased the phosphorylation levels of AP-1 subunits (c-Fos, c-Jun) and p38-MAP kinase, while increasing the detection of the ALX/FPR2 receptor. Moreover, various pharmacological agents revealed the blunting effects of RvD(2) on LTD4 or TNF-alpha induced hyper-responsiveness. Combined treatment with 300 nM RvD(2) and 1 mu M WRW4 (an ALX/FPR2 receptor inhibitor) blunted the pro-resolving and broncho-modulatory effects of RvD(2). The present data provide new evidence regarding the role of RvD(2) in a human model of airway inflammation and hyperrresponsiveness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available